Experts foresee premium pricing for overdose-fighting injector Evzio

Amid fierce debate over hepatitis C drug costs, another example of potentially questionable pricing looms, The New York Times contends. The new anti-overdose injector, Evzio, is as-yet unpriced, but it could well follow in the footsteps of other newly approved--and newly pricey--formulations of long-off-patent meds. Experts are predicting a $500-per-dose price on a drug that might otherwise cost $3-per-dose. Report (sub. req.)